Skip to main content
Right now, a biotech team somewhere in Australia is weeks into trying to find a service provider capable of running a specific in vivo toxicology model. The capability exists, but it may be inside an interstate university facility, or at a specialist CRO with no meaningful online presence. The team will eventually find it, through a referral or a conference conversation, but they will lose weeks getting there. Those weeks have a cost that never appears on any budget line. This is not an edge case. It is the default experience for scientific outsourcing in Australia, and it is structurally embedded in how the sector operates today.

​
A highly capable but poorly connected ecosystem

Australia’s life science sector is genuinely strong. AusBiotech’s Sector Snapshot counted 1,427 industry-based companies, approximately 260,000 people employed across the broader life sciences ecosystem, and an ASX-listed market capitalisation of about A$233 billion across 192 listed life sciences companies, growth of 60 per cent since 2017. Universities produce world-class research, medical research institutes carry global reputations, and contract research and manufacturing organisations, spanning preclinical biology, formulation development, analytical testing, and beyond, serve both domestic and international clients. That breadth is a real national asset. What is far less acknowledged is how poorly connected that capability is. Each institution, CRO, and specialist facility operates within its own silo:
  • Capability statements live as PDFs on institutional websites, or do not exist in any accessible form at all
  • Service offerings are described inconsistently
  • Accreditations are buried or missing
  • Pricing and capacity are almost never visible to an outside party without a direct enquiry
The result is a sector where finding the right Provider is less a search problem and more a networking problem. What any given team can access depends heavily on who they know. Eighty-seven per cent of medtech, biotech, and pharmaceutical companies in Australia are SMEs, according to the joint AusBiotech and MTPConnect Discussion Paper. Their networks and visibility can run on the bandwidth of one or two senior staff. What they do not know they are missing is, by definition, invisible to them.

​
The cost that never gets accounted for

For biotech and pharma teams, fragmentation is both operational and financial. Discovery through informal networks or exhaustive search takes time that could be generating data. Weeks spent identifying potential providers delay project initiation, push out timelines, and in a sector where capital is finite and investor milestones are fixed, that delay compounds. The risk of a bridging round is rarely framed as a procurement problem, but slow R&D outsourcing is one of its quieter contributors. Comparison makes it worse. Even once a shortlist is assembled, evaluating providers side by side is difficult. One describes its services at a high level; another lists every individual assay. One leads with NATA accreditation; another does not mention it at all. GLP or GMP compliance, often critical for regulatory or RDTI purposes, may or may not be disclosed. Without a common structure across providers, research teams assemble their picture from fragments. That slows decisions and increases the risk of scope misalignment once work begins. This is not a criticism of individual providers. Most are doing exactly what makes sense in the absence of shared infrastructure: managing their own web presence, their own capability documentation, their own outreach. The problem is systemic. The sector lacks the coordination layer that would make its collective capability legible.

​
Providers carry the cost too

It is tempting to frame fragmentation purely as a problem for the teams trying to find services. Less well recognised is what it costs the Providers themselves. A CRO or specialist lab with genuinely strong capabilities faces a structural visibility problem: how does a biotech team interstate, or an international pharma company scoping Australian R&D options, discover that they exist? The traditional answers we have been hearing are conference attendance, cold outreach, word-of-mouth referrals, and SEO investment. These can be expensive, time-consuming, and inconsistent. The providers most discoverable through those channels are not necessarily the most capable; they are the most resourced for marketing. That is a poor proxy for quality. It systematically disadvantages smaller, newer, or more specialist operators who may be precisely what a project needs. Australia has invested significantly in research capability through universities, NCRIS facilities, and the broader innovation ecosystem, but a meaningful proportion of the nation’s capacity remains below the visibility threshold of the teams most likely to need it.

​
What a centralised platform actually changes

The case for a centralised scientific services platform covering the entirety of Australia’s network is not that it replaces relationships or removes the need for due diligence. It is that it makes the starting point dramatically better for everyone. A structured, searchable directory, organised around a consistent Capability Taxonomy, allows research teams to filter by service type, domain, modality, accreditation, and location. It makes niche capabilities discoverable to teams that would never have thought to look for them. It creates a common display standard that lets Providers present their services consistently, and lets Members evaluate them on equivalent terms. Pipeline Bio is built around exactly this gap. The Platform’s Directory of Providers and underlying Capability Taxonomy bring structure to a sector that has operated without it, giving research teams a faster path from need to shortlist, and giving Providers a structured presence that does not require ongoing marketing investment to maintain. Pipeline Bio currently lists capabilities from over 250 Providers across 13 broad categories including preclinical, manufacturing and CMC, clinical, analytical services, logistics, legal, finance, and others. When capability is legible, it gets used more efficiently. When providers are discoverable on the basis of what they actually do rather than how well they rank in search, the quality of R&D procurement improves across the board.

​
Discovery is only the first friction point

Identifying a Provider does not end the problem. Initiating a project remains heavily manual. Enquiries go out as unstructured emails. Capability clarifications accumulate across long threads. Requests for Proposal vary wildly in structure and completeness, making them difficult for providers to respond to accurately and difficult for Members to compare meaningfully. The downstream effects are predictable: scope misalignment, delayed project starts, and administrative overhead that consumes time better spent on science. A platform that supports structured enquiry and RFP submission, with templated study briefs and defined data fields, compresses the time from initial contact to project commencement on both sides. Pipeline Bio’s enquiry and RFP tools are built around this problem, reducing the back-and-forth that currently characterises early-stage engagement across the sector.

​
RDTI compliance and the invisible provider problem

There is a specific regulatory dimension in which fragmentation creates direct compliance risk: the R&D Tax Incentive. Under the RDTI, companies seeking an Overseas Finding, authorisation to claim expenses incurred offshore, must first demonstrate that the required capability is not available in Australia. That requirement is reasonable in principle. In practice, it is genuinely difficult to satisfy when the landscape of domestic providers is opaque. Teams may not know a local option exists. They may have found one too late to document the search. Without a transparent, searchable record of Australian scientific services, the evidence base for any Overseas Finding application may be weak. The scale of this matters. The ATO’s R&D Tax Incentive Transparency Report 2022–23 shows Professional, Scientific and Technical Services as the leading industry for R&D expenditure claimed under the program, approximately A$6.2 billion across around 5,600 claimants. RDTI compliance is not a niche concern. A centralised platform changes the nature of the search. When a team can document a structured inquiry across a comprehensive Australian directory and confirm no local provider meets their requirements, the Overseas Finding application rests on solid ground. Pipeline Bio’s RFP Summary Report feature is designed specifically for this, helping teams identify local capability gaps and produce a documented record of their search process.
Pipeline Bio makes no guarantees regarding RDTI or Overseas Finding eligibility. Refer to the official RDTI guidance from the Australian Government.

​
Infrastructure the sector has been missing

Australia is in a period of deliberate investment in its life science and biotechnology sector. The National Reconstruction Fund, the Medical Research Future Fund, and successive state-level strategies have all identified life science and advanced manufacturing as priority areas. MTPConnect’s Sector Competitiveness Plan recorded 4 per cent annual growth in MTP sector jobs between 2016 and 2021, well above the national average of 1.2 per cent. MTPConnect’s FY2024 Annual Report attributes approximately A$7.5 billion of total economic impact to its strategic funding programs alone. That investment is well-directed. But capital investment in scientific capability without investment in the infrastructure to connect that capability has a ceiling. The ability to find, evaluate, and engage Australian scientific services efficiently is not a secondary concern. It is foundational to how quickly research teams can move from discovery to development to commercialisation. The joint Pre-Budget Submission from MTPConnect and AusBiotech makes the gap explicit: Australia ranks in the global top ten for scientific research but has fallen to 30th for research outputs. The constraint is not capability. It is the infrastructure connecting capability to commercialisation. A centralised platform for scientific services does not resolve every problem in the sector. It does not change the underlying science, the regulatory environment, or the capital markets. What it does is remove a specific and pervasive layer of friction that costs research teams time, costs Providers visibility, and costs the sector the efficient use of its own capability. Australia has the scientific depth. Pipeline Bio’s mission is to ensure that its capability is as visible and accessible as it needs to be.

​
Frequently asked questions

Pipeline Bio is a platform that helps biotech, pharmaceutical, and research organisations discover and engage scientific service providers. It centralises the scientific services ecosystem into a structured Directory of Providers built on a consistent Capability Taxonomy.
The Platform organises Providers into a structured Directory, with a consistent Capability Taxonomy that lets research teams filter by service type, capability, accreditation, regulatory context, and location. The AI Search Agent also accepts free-text enquiries and surfaces relevant providers from the Directory.
Companies seeking an Overseas Finding under the R&D Tax Incentive must demonstrate that the required capability is not available in Australia. The RFP Summary Report feature helps teams document a structured search of Australian capability and produce a verifiable record to support their Overseas Finding application.
Pipeline Bio is open to both Members (biotech, pharma, medtech, and research teams looking to engage external services) and Providers (CROs, CDMOs, academic core facilities, and specialist consultancies). Members from anywhere in the world can use the Platform to find and engage Providers.
Pipeline Bio organises Providers around a structured Capability Taxonomy rather than free-text listings, supports procurement workflows (enquiries, RFPs, and quote collection) rather than just visibility, and produces documented evidence reports for the R&D Tax Incentive Overseas Finding process. It is built specifically for the life sciences ecosystem and for engagement by local and international biotech.

​
Related

Australia's R&D Tax Incentive

Refunds, reforms, and how outsourced research is treated.

The Capability Taxonomy

How capabilities are classified, compared, and engaged.